1-11 of 11
Armelle Logie
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5553: Monotherapy efficacy of catalytic and allosteric inhibitors of AKT in breast cancer models with AKT1E17K mutations

Barry R. Davies, Nin Guan, Armelle Logie, Amy Palmer, Vivien Jacobs, Neil James, Emma L. Jenkins
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5553.
DOI: https://doi.org/10.1158/1538-7445.AM2014-5553
Published: 01 October 2014
View article
Journal Articles

Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer

Sylvie M. Guichard, Zoe Howard, Dan Heathcote, Mark Roth, Gareth Hughes, Jon Curwen, James Yates, Armelle Logie, Sarah Holt, Christine M. Chresta, Barry R. Davies, Karine Malagu, Marc Hummersone, Sarah L. Pass, Stephen Green, Martin Pass
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 917.
DOI: https://doi.org/10.1158/1538-7445.AM2012-917
Published: 15 April 2012
View article
Journal Articles

Abstract 3224: Pre-clinical targeting of the metabolic phenotype of lymphoma by AZD3965, a selective inhibitor of monocarboxylate transporter 1 (MCT1)

Susan E. Critchlow, Lorna Hopcroft, Lorraine Mooney, Nicola Curtis, Nicky Whalley, Haihong Zhong, Armelle Logie, Mitchell Revill, Liang Xie, Jingchuan Zhang, De-Hua Yu, Clare Murray, Paul D. Smith
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3224.
DOI: https://doi.org/10.1158/1538-7445.AM2012-3224
Published: 15 April 2012
View article
Journal Articles

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

Sarah V. Holt, Armelle Logie, Barry R. Davies, Denis Alferez, Sarah Runswick, Sarah Fenton, Christine M. Chresta, Yi Gu, Jingchuan Zhang, Yi-Long Wu, Robert W. Wilkinson, Sylvie M. Guichard, Paul D. Smith
Journal: Cancer Research
Cancer Res (2012) 72 (7): 1804–1813.
DOI: https://doi.org/10.1158/0008-5472.CAN-11-1780
Published: 01 April 2012
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

Juliane M. Jürgensmeier, Jane Kendrew, Rajesh Odedra, Armelle Logie, Philippa Wood, Paula Valentine, Sharon Barnett, Robert W. Wilkinson, Donald J. Ogilvie, Paul Elvin, Paul Smith, Anderson Ryan, Stephen R. Wedge
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1372.
DOI: https://doi.org/10.1158/1538-7445.AM10-1372
Published: 15 April 2010
View article
Journal Articles

Abstract 4434: Combined targeting of Aurora B (AZD1152) and MEK1/2 (AZD6244) kinases leads to enhancement of anti-tumour effects in vivo.

Rajesh Odedra, Simon Heaton, Armelle Logie, Kirsten E. Mundt, Elizabeth Anderson, Paul D. Smith, Robert W. Wilkinson
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4434.
DOI: https://doi.org/10.1158/1538-7445.AM10-4434
Published: 15 April 2010
View article
Journal Articles

Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials

Eli Wallace, Joseph Lyssikatos, James Blake, Allison Marlow, Julie Greschuk, Tammie Yeh, Michele Callejo, Vivienne Marsh, Gregory Poch, Jennifer Otten, Gary Hingorani, Shannon Winski, Deborah Anderson, Patrice Lee, James Winkler, Kevin Koch, Barry Davies, Darren Jones, Armelle Logie, Nicola Curtis, Christine Chresta, Paul Smith, David Robinson
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3696.
Published: 01 May 2009
View article
Journal Articles

Abstract #2757: Combination therapy with inhibitors of mTOR and MEK1/2 (AZD6244) kinases, shows enhanced apoptosis and tumor growth inhibition in preclinical models

Robert Wilkinson, Sarah Holt, Nicola Curtis, Armelle Logie, Patrizia Sini, Barry Davies, Christine Chresta, Sylvie Guichard, Paul Smith
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2757.
Published: 01 May 2009
View article
Journal Articles

Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of in vivo sequencing of drug administration

Robert Wilkinson, Armelle Logie, Nicola Haupt, Nicola Curtis, Mark Hickinson, Barry Davies, Jennifer McKay, Paul Smith
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4012.
Published: 01 May 2008
View article
Journal Articles

Combining the potent MEK1/2 inhibitor AZD6244 (ARRY-142886) with radiotherapy in a lung tumor xenograft model; pharmacodynamic effects, therapeutic benefits and the hypoxia response

Aoife Shannon, Brian Telfer, Muhammed Babur, Paul Smith, Armelle Logie, Robert Wilkinson, Ian Stratford, Kaye Williams, Steve Wedge
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2568.
Published: 01 May 2008
View article
Journal Articles

Pharmacokinetics, tissue distribution and anti-tumor activity of the Src/Abl kinase inhibitor AZD0530 in a rat xenograft model

Armelle Logie, Paul D. Martin, Elizabeth A. Partridge, Stephanie L. Byatt, Robin D. Whittaker, Tim P. Green
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1409.
Published: 01 May 2005
View article